Skip to main
  1. Stocks
  2. Adicet Bio, Inc.
  3. Forecast
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio is supported by compelling prula-cel data in lupus nephritis and systemic lupus erythematosus, where 50% of evaluable LN patients achieved complete renal response at 12 months and 54% reached DORIS remission, with responses ongoing through 12 to 21 months and all patients discontinuing immunosuppressants. Its safety profile also appears differentiated, with no CRS above Grade 2, no ICANS, no IEC-HS, and only 8.3% Grade 3 or higher infections, reinforcing the appeal of an off-the-shelf, outpatient-friendly allogeneic platform. The outlook is further strengthened by pivotal study start-up next quarter, a planned FDA meeting in 4Q26 on expanding into lupus without nephritis, and ADI-212 receiving IND clearance and Fast Track designation, all of which enhance the 2027 catalyst set.

Bears say

Adicet Bio is viewed negatively because it remains a pre-revenue clinical-stage biotech with no proven commercial engine, yet it posted a net loss of $18.9MM, or ($1.76) per share, alongside $15.6MM of R&D expense and $4.2MM of G&A expense. Although it ended the quarter with approximately $100.9MM in cash and expects runway into 2H27, the business still faces material financing risk until it becomes cash flow positive, while clinical and regulatory failure of ADI-001, delayed trial initiation, or unexpected safety issues could materially impair value. The outlook is further pressured by management’s removal of SSc from valuation and the continued dependence on unproven programs like prula-cel and ADI-212, which leaves execution, competition, and commercialization risks unresolved.

ACET has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

ACET Analyst Forecast & Price Prediction

Get the latest ACET stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ACET

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 5 analysts, ACET has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


ACET Analyst Forecast & Price Prediction

Get the latest ACET stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ACET

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ACET stock data and trends